52 In a large meta-analysis by Chiang et al involving 106,395 participants and 55 RCTs, GLP-1 RA therapy was associated with an increased risk of gastroesophageal reflux disease (GERD) compared to placebo, with a reported relative risk of 2.19 (95% CI: 1.483.25)
Evidence suggests that rapid and substantial weight loss, rather than the medication alone, drives most hepatobiliary events
You may be a suitable candidate if: Your BMI is 30 or higher (classified as obesity) Your BMI is 27+ with related health issues (e.g., diabetes, high blood pressure) You have not seen results with diet and exercise alone You are committed to long-term lifestyle changes When used alongside healthy nutrition and physical activities, these medications yield excellent results
Alle angebotenen Rollgerste entsprechen der Lastklasse 3 und sind nach DIN 4422 zertifiziert
The weekly injections are designed to be convenient, allowing patients to incorporate the treatment into their routine with minimal disruption